Aptorum Group Updates On A Phase 1b/2a Clinical Trial For Repurposed Small Molecule Drug SACT-1 For Neuroblastoma
Portfolio Pulse from Happy Mohamed
Aptorum Group has submitted the Phase 1b/2a clinical trial protocol of SACT-1, an orally administered repurposed small molecule drug for the treatment of neuroblastoma, to the US FDA. The trial will study SACT-1 in combination with chemotherapy for first relapse or refractory high-risk neuroblastoma patients.
June 22, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aptorum Group's submission of the Phase 1b/2a clinical trial protocol of SACT-1 to the US FDA may positively impact the company's stock price in the short term.
The submission of the Phase 1b/2a clinical trial protocol of SACT-1 to the US FDA represents a key milestone for Aptorum Group and may lead to increased investor confidence in the company's ability to develop novel treatments for oncological diseases. This may result in a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100